Guard Therapeutics International AB (publ)

Stockholm Stock Exchange GUARD.ST

Guard Therapeutics International AB (publ) Operating Income for the year ending December 31, 2023: USD -11.36 M

Guard Therapeutics International AB (publ) Operating Income is USD -11.36 M for the year ending December 31, 2023, a -3.49% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Guard Therapeutics International AB (publ) Operating Income for the year ending December 31, 2022 was USD -10.97 M, a -21.71% change year over year.
Guard Therapeutics International AB (publ) Operating Income for the year ending December 31, 2021 was USD -9.02 M, a -84.72% change year over year.
Guard Therapeutics International AB (publ) Operating Income for the year ending December 31, 2020 was USD -4.88 M, a -3.60% change year over year.
Guard Therapeutics International AB (publ) Operating Income for the year ending December 31, 2019 was USD -4.71 M, a 51.33% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Stockholm Stock Exchange: GUARD.ST

Guard Therapeutics International AB (publ)

CEO	Mr. Tobias Larsson Agervald
IPO Date	April 3, 2013
Location	Sweden
Headquarters	Nybrogatan 34, 2 tr
Employees	11
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.

Key trends

Past 5 years